Managed Care

 

Peer-Reviewed Articles from Managed Care

Research Articles from Managed Care

John Barron, PharmD ; Ralph Turner, PhD ; Michael Jaeger, MD ; Wallace Adamson, MD ; Joseph Singer, MD

Patients treated with oral linezolid, covered under the pharmacy benefit, had lower re-hospitalizations and emergency room visits than patients treated with vancomycin or daptomycin, covered under the medical benefit

Setareh A. Williams, PhD ; Erin K. Buysman, MS ; Erin M. Hulbert, MS ; Joette Gdovin Bergeson, PhD ; Bin Zhang, MD ; John Graham, PharmD

This study verifies, as defined by current guidelines, that initial treatment with fixed dose combinations (FDC) is associated with a better likelihood of HbA1c goal attainment and lower health care resource use and costs.

James P. Reichmann, MBA ; Michael S. Kirkbride, BSc, Pharm D

A review of the available research identifies payment for services in the absence of high-quality scientific evidence and presents an opportunity to use evidence-based medicine to develop a clinical coverage guideline

Debra Wertz, PharmD ; Likun Hou, MS ; Andrea DeVries, PhD ; Leon Dupclay Jr., PharmD, PhD ; Frannie McGowan, PharmD, CDE ; Barry Malinowski, MD ; Mark J. Cziraky, PharmD, FAHA
The program showed significant improvements in all diabetes and hypertension-related clinical measures
Eric Q. Wu, PhD ; Rym Ben-Hamadi, MSc ; Mei Lu, MS ; Nicolas Beaulieu, MA ; Andrew P. Yu, PhD ; M. Haim Erder, PhD
Escitalopram patients in a Florida Medicaid population had better treatment persistence and lower total health care costs than patients prescribed citalopram
Andrew Kolbasovsky, PsyD, MBA
Determining return on investment and improvement of outcomes is essential when new programs are being tried, but the research method must be chosen carefully
Michael Toscani, PharmD ; Marc Riedl, MD, MS
With the advent of new disease-specific agents, some patients with HAE may find relief from its enormous physical and psychological toll
Anand A. Dalal, PhD ; Sean D. Candrilli, PhD ; Keith L. Davis, MA
The comparison found that maintenance therapy with fluticasone propionate-salmeterol combination was associated with a 14% reduction in risk of severe exacerbation, less health care utilization, and 25% lower COPD-related medical costs
Girishanthy Krishnarajah, MPH, MBA/MS ; Monali Bhosle, PhD ; Richard Chapman, PhD
A comparison of health care costs in patients with diabetes who do not initially respond to oral therapy suggests that it might be appropriate and clinically beneficial for providers to consider adding another oral agent, rather than up-titrating the current medication, particularly beyond intermediate dose levels
Richard C. Weiss, BS, MS ; Derek van Amerongen MD, MS ; Gary Bazalo, BS, MS, MBA ; Mark Aagren, MS ; Jonathan R. Bouchard, MS, RPh

Pages

Meetings

2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
6th Semi-Annual Diagnostic Coverage and Reimbursement Conference Boston December 4–5, 2014
Customer Analytics & Engagement in Health Insurance Chicago December 4–5, 2014
Pharmaceutical and Biotech Clinical Quality Assurance Conference Alexandria, VA December 4–5, 2014
9th Semi-Annual Medical Device Coverage and Reimbursement Conference San Diego December 5, 2014
8th Annual Medical Device Clinical Trials Conference Chicago December 8–9, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015